116 related articles for article (PubMed ID: 35643842)
21. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
[TBL] [Abstract][Full Text] [Related]
22. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
Hagiwara M; Hackshaw MD; Oster G
J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and economic burden of hyperkalemia in the United States Medicare population.
Mu F; Betts KA; Woolley JM; Dua A; Wang Y; Zhong J; Wu EQ
Curr Med Res Opin; 2020 Aug; 36(8):1333-1341. PubMed ID: 32459116
[No Abstract] [Full Text] [Related]
24. The burden of illness associated with renal cell carcinoma in the United States.
Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
[TBL] [Abstract][Full Text] [Related]
25. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
26. Characteristics and Healthcare Burden of Patients with Schizophrenia Treated in a US Integrated Healthcare System.
Mahabaleshwarkar R; Lin D; Joshi K; Fishman J; Blair T; Hetherington T; Palmer P; Patel C; Krull C; Tcheremissine OV
J Ment Health Policy Econ; 2021 Jun; 24(2):47-59. PubMed ID: 34151777
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
Jabbour EJ; Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
J Med Econ; 2017 Sep; 20(9):1007-1012. PubMed ID: 28681664
[TBL] [Abstract][Full Text] [Related]
28. The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis.
Yang M; Georgieva MV; Bocharova I; Vembusubramanian M; Qian K; Guo A; Kamat AM
Adv Ther; 2021 Mar; 38(3):1584-1600. PubMed ID: 33543424
[TBL] [Abstract][Full Text] [Related]
29. Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan.
Insinga RP; Ye X; Singhal PK; Carides GW
Gynecol Oncol; 2008 Nov; 111(2):188-96. PubMed ID: 18757080
[TBL] [Abstract][Full Text] [Related]
30. Comparison of approaches for estimating incidence costs of care for colorectal cancer patients.
Yabroff KR; Warren JL; Schrag D; Mariotto A; Meekins A; Topor M; Brown ML
Med Care; 2009 Jul; 47(7 Suppl 1):S56-63. PubMed ID: 19536010
[TBL] [Abstract][Full Text] [Related]
31. Higher Resource Utilization and Costs in Long-Term Nursing Home Residents With Overactive Bladder: A Retrospective Study of Medicare Beneficiaries.
Sura S; Shiozawa A; Ng D; Aparasu RR
J Am Med Dir Assoc; 2021 Jun; 22(6):1300-1306. PubMed ID: 33071158
[TBL] [Abstract][Full Text] [Related]
32. Kidney Failure Attributed to Immunoglobulin A Nephropathy: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden.
Bensink ME; Goldschmidt D; Zhou ZY; Wang K; Lieblich R; Bunke MC
Kidney Med; 2024 Feb; 6(2):100759. PubMed ID: 38282694
[TBL] [Abstract][Full Text] [Related]
33. Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.
Li P; Jahnke J; Pettit AR; Wong YN; Doshi JA
JAMA Netw Open; 2019 Jun; 2(6):e195806. PubMed ID: 31199450
[TBL] [Abstract][Full Text] [Related]
34. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
Aly A; Johnson C; Yang S; Botteman MF; Rao S; Hussain A
J Med Econ; 2019 Jul; 22(7):662-670. PubMed ID: 30836812
[No Abstract] [Full Text] [Related]
35. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.
Pilon D; Joshi K; Sheehan JJ; Zichlin ML; Zuckerman P; Lefebvre P; Greenberg PE
PLoS One; 2019; 14(10):e0223255. PubMed ID: 31600244
[TBL] [Abstract][Full Text] [Related]
36. Phase-Specific and Lifetime Costs of Multiple Myeloma Among Older Adults in the US.
Bhattacharya K; Bentley JP; Ramachandran S; Chang Y; Banahan BF; Shah R; Bhakta N; Yang Y
JAMA Netw Open; 2021 Jul; 4(7):e2116357. PubMed ID: 34241627
[TBL] [Abstract][Full Text] [Related]
37. Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors.
Amin AN; Jhaveri M; Lin J
Adv Ther; 2011 Oct; 28(10):907-26. PubMed ID: 21971681
[TBL] [Abstract][Full Text] [Related]
38. Fall Risk, Healthcare Resource Use, and Costs Among Adult Patients in the United States Treated for Insomnia with Zolpidem, Trazodone, or Benzodiazepines: A Retrospective Cohort Study.
Amari DT; Juday TR; Frech FH; Wang W; Gor D; Atkins N; Wickwire EM
Adv Ther; 2022 Mar; 39(3):1324-1340. PubMed ID: 35072889
[TBL] [Abstract][Full Text] [Related]
39. Direct costs of carcinoid syndrome diarrhea among adults in the United States.
Dasari A; Joish VN; Perez-Olle R; Dharba S; Balaji K; Halperin DM
World J Gastroenterol; 2019 Dec; 25(47):6857-6865. PubMed ID: 31885426
[TBL] [Abstract][Full Text] [Related]
40. INITIAL ADOPTION OF RECOMBINANT HUMAN THYROID-STIMULATING HORMONE FOLLOWING THYROIDECTOMY IN THE MEDICARE THYROID CANCER PATIENT POPULATION.
Dinan MA; Li Y; Reed SD; Sosa JA
Endocr Pract; 2019 Jan; 25(1):31-42. PubMed ID: 30383499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]